Superworth

China Pharma revenue CPHI

Sales by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
$3.9M
Latest quarter, Q2 FY26
$948.3K
−8% on a year earlier
Fiscal year 2025
$4.1M
−8% on the year before

China Pharma's revenue was $3.9M over the twelve months to Jun 30, 2026, down 11% on a year earlier.

In its latest quarter, Q2 FY26, it was $948.3K, down 8% on the same quarter a year before.

Over the five fiscal years to FY2025 it shrank 18% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$4.1M−8%
FY2024$4.5M−35%
FY2023$7M−13%
FY2022$8.1M−16%
FY2021$9.6M−11%
FY2020$10.9M−1%
FY2019$10.9M−11%
FY2018$12.3M−7%
FY2017$13.2M−15%
FY2016$15.6M−23%
FY2015$20.4M−18%
FY2014$24.9M−24%
FY2013$32.8M−40%
FY2012$54.5M−33%
FY2011$81.2Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$948.3K−8%$3.9M
Q1 FY26$983.5K−13%$4M
Q4 FY25$1.2M+8%$4.1M
Q3 FY25$756.2K−31%$4.1M
Q2 FY25$1M+11%$4.4M
Q1 FY25$1.1M−17%$4.3M
Q4 FY24$1.1M−47%$4.5M
Q3 FY24$1.1M−39%$5.5M
Q2 FY24$924.9K−16%$6.2M
Q1 FY24$1.4M−30%$6.4M
Q4 FY23$2.1M−26%$7M
Q3 FY23$1.8M−8%$7.8M

Against its peers

Companies in Drug Manufacturers - General nearest China Pharma's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
CPHIChina Pharma$3.9M−11% a year
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeutics$47M−3% a year
LFVNLifevantage$182.6M−20% a year
NATRNatures Sunshine Products$492M+7% a year
Peer median$182.6M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on China Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.